Zenas BioPharma, Inc. Zenas BioPharma, Inc.

Zenas BioPharma, Inc.

ZBIO

Rank in Stocks #6071
Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm,... Zenas BioPharma, Inc. functions as a clinical-stage biopharmaceutical firm, concentrating on the creation and market introduction of innovative, immunology-based treatments. The company's primary investigational therapy is obexelimab, a distinctive bifunctional monoclonal antibody intended to address multiple diseases such as immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. Its developmental portfolio also features ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody. Established in 2019, the entity was formerly recognized as Zenas BioPharma (Cayman) Limited before adopting its current name, Zenas BioPharma, Inc., in August 2023. Its headquarters are located in Waltham, Massachusetts.
Share Price
$28.01
Last synced: 2026-11-13
Market Cap
$1.85B
Change (1 day)
1.34%
Change (1 year)
-19.60%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Category

Healthcare
EPS for Zenas BioPharma, Inc. (ZBIO)
EPS as of September 2026 TTM: $-10.05
According to Zenas BioPharma, Inc.'s latest financial reports, its current EPS (TTM) is $-10.05. At the end of 2025 the company had an EPS of $-8.44, a decrease compared to its 2024 EPS of $-3.76.
EPS history for Zenas BioPharma, Inc. from 2022 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $-10.05 19.08%
2025 $-8.44 124.47%
2024 $-3.76 287.63%
2023 $-0.97 -68.81%
2022 $-3.11 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$-0.89 -91.14%
US
$15.66 -255.82%
US
$-7.07 -29.65%
US
$-5.29 -47.36%
AU
$12.73 -226.69%
BE

Questions about Zenas BioPharma, Inc.'s earnings per share (EPS)

What is Zenas BioPharma, Inc.'s earnings per share (EPS)?

Zenas BioPharma, Inc.'s earnings per share (EPS) over the last twelve months is $-10.05, as of Sep 2026.

What was Zenas BioPharma, Inc.'s earnings per share (EPS) in 2025?

In 2025, Zenas BioPharma, Inc.'s earnings per share (EPS) was $-8.44, compared with $-3.76 in 2024.

How has Zenas BioPharma, Inc.'s earnings per share (EPS) changed since 2022?

From 2022 to 2025, Zenas BioPharma, Inc.'s earnings per share (EPS) was highest in 2023 ($-0.97) and lowest in 2025 ($-8.44).

How does Zenas BioPharma, Inc.'s earnings per share (EPS) compare with similar companies?

Zenas BioPharma, Inc.'s earnings per share (EPS) ($-10.05) is lower than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with $15.66.